Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.36 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.36 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.36 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.36 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.36 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 7/20 | 0.35 |
| ▸ | MGAM | O43451 | 4/20 | 0.35 |
| ▸ | SI | P14410 | 4/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11073742 | 0.83 | IDO1 (0.46) | IDO1GAAESR1ESR2KDM4E | |
| SCHEMBL5833744 | 0.83 | HTR1B (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5833170 | 0.79 | NOS3 (0.35) | GAAMGAMSIMGAM2KDM4E | |
| SCHEMBL6152641 | 0.76 | NOS3 (0.38) | GAAMGAMSIMGAM2 | |
| SCHEMBL8122697 | 0.75 | CCR1 (0.54) | NPC1RAB9A | |
| SCHEMBL5833350 | 0.75 | PTGER1 (0.42) | MAPTHTT | |
| SCHEMBL5833033 | 0.73 | KDM4E (0.34) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6584801 | 0.72 | AR (0.34) | GAAMGAMSIMGAM2KDM4E | |
| SCHEMBL6622613 | 0.72 | MAP3K5 (0.38) | HPGDHSD17B10ALDH1A1MEN1MAPT | |
| SCHEMBL6696951 | 0.71 | RAB9A (0.49) | GAAMGAMSIMGAM2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012078-B2 | 2-aminopyridines containing fused ring substituents | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1007520-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PROD INC (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030149017-A1 | 2-Aminopyridines containing fused ring substituents | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | LOWE JOHN ADAMS (US) | 2001-12-06 | — | — | US | disclosed |
| EP-1007520-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | Pfizer Products Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999010339-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149017-A1 | 2-Aminopyridines containing fused ring substituents | NOS2, NOS1, NOS3 | IDO1 534/4885TUBB4A 1834/4885TUBB 1462/4885 |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | NOS2, NOS1, NOS3 | IDO1 534/4885TUBB4A 1834/4885TUBB 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.